# ResQ201A (NCT06745908)

> Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy

No report yet. It can be ordered.

- Drugs tested: nogapendekin alfa inbakicept (N-803) plus tislelizumab; nogapendekin alfa inbakicept (N-803)
- Indication: immune checkpoint inhibitor-resistant stage IV NSCLC

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06745908
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: ImmunityBio, Inc.
- Conditions: NSCLC Stage IV
- Interventions: N-803; Tislelizumab; Docetaxel; Prior failed checkpoint inhibitor
- Enrollment: 507
- Primary outcome: Compare Overall Survival between the experimental and control arms

## Indexed commentary on ResQ201A so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 6 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=resq201a-nct06745908
